These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 28241889)
1. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Shindo Y; Hazama S; Suzuki N; Iguchi H; Uesugi K; Tanaka H; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Takenouchi H; Matsui H; Kanekiyo S; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Fujita T; Kawakami Y; Nakamura Y; Oka M; Nagano H J Exp Clin Cancer Res; 2017 Feb; 36(1):36. PubMed ID: 28241889 [TBL] [Abstract][Full Text] [Related]
2. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Suzuki N; Hazama S; Iguchi H; Uesugi K; Tanaka H; Hirakawa K; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Shimizu R; Hayashi H; Sakata K; Takenouchi H; Matsui H; Shindo Y; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Nakamura Y; Oka M; Nagano H Cancer Sci; 2017 Jan; 108(1):73-80. PubMed ID: 27783849 [TBL] [Abstract][Full Text] [Related]
3. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer]. Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005 [TBL] [Abstract][Full Text] [Related]
4. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines. Fourcade J; Sun Z; Pagliano O; Chauvin JM; Sander C; Janjic B; Tarhini AA; Tawbi HA; Kirkwood JM; Moschos S; Wang H; Guillaume P; Luescher IF; Krieg A; Anderson AC; Kuchroo VK; Zarour HM Cancer Res; 2014 Feb; 74(4):1045-55. PubMed ID: 24343228 [TBL] [Abstract][Full Text] [Related]
5. Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients. Daiko H; Marafioti T; Fujiwara T; Shirakawa Y; Nakatsura T; Kato K; Puccio I; Hikichi T; Yoshimura S; Nakagawa T; Furukawa M; Stoeber K; Nagira M; Ide N; Kojima T Cancer Immunol Immunother; 2020 Nov; 69(11):2247-2257. PubMed ID: 32500232 [TBL] [Abstract][Full Text] [Related]
6. Expression of programmed cell death protein 1 and T-cell immunoglobulin- and mucin-domain-containing molecule-3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneously cleared the virus. Caraballo Cortés K; Osuch S; Perlejewski K; Pawełczyk A; Kaźmierczak J; Janiak M; Jabłońska J; Nazzal K; Stelmaszczyk-Emmel A; Berak H; Bukowska-Ośko I; Paciorek M; Laskus T; Radkowski M J Viral Hepat; 2019 Aug; 26(8):942-950. PubMed ID: 30972915 [TBL] [Abstract][Full Text] [Related]
7. Programmed cell death-1 (PD-1) and T-cell immunoglobulin mucin-3 (Tim-3) regulate CD4+ T cells to induce Type 2 helper T cell (Th2) bias at the maternal-fetal interface. Wang S; Zhu X; Xu Y; Zhang D; Li Y; Tao Y; Piao H; Li D; Du M Hum Reprod; 2016 Apr; 31(4):700-11. PubMed ID: 26908841 [TBL] [Abstract][Full Text] [Related]
8. Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. Asahara S; Takeda K; Yamao K; Maguchi H; Yamaue H J Transl Med; 2013 Nov; 11():291. PubMed ID: 24237633 [TBL] [Abstract][Full Text] [Related]
9. The expression of Tim-3 in peripheral blood of ovarian cancer. Wu J; Liu C; Qian S; Hou H DNA Cell Biol; 2013 Nov; 32(11):648-53. PubMed ID: 24007284 [TBL] [Abstract][Full Text] [Related]
10. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer. Xu B; Yuan L; Gao Q; Yuan P; Zhao P; Yuan H; Fan H; Li T; Qin P; Han L; Fang W; Suo Z Oncotarget; 2015 Aug; 6(24):20592-603. PubMed ID: 26008981 [TBL] [Abstract][Full Text] [Related]
11. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. Terasaki M; Shibui S; Narita Y; Fujimaki T; Aoki T; Kajiwara K; Sawamura Y; Kurisu K; Mineta T; Yamada A; Itoh K J Clin Oncol; 2011 Jan; 29(3):337-44. PubMed ID: 21149665 [TBL] [Abstract][Full Text] [Related]
12. [Up-regulation of TIM-3 on CD4+ tumor infiltrating lymphocytes predicts poor prognosis in human non-small-cell lung cancer]. Ji P; Chen D; Bian J; Xia R; Song X; Wen W; Zhang X; Zhu Y Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jun; 31(6):808-11. PubMed ID: 26062425 [TBL] [Abstract][Full Text] [Related]
13. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines. Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448 [TBL] [Abstract][Full Text] [Related]
14. TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice. Tanaka Y; Wada H; Goto R; Osada T; Yamamura K; Fukaya S; Shimizu A; Okubo M; Minamiguchi K; Ikizawa K; Sasaki E; Utsugi T Sci Rep; 2020 Oct; 10(1):17284. PubMed ID: 33057061 [TBL] [Abstract][Full Text] [Related]